skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Resultados 1 2 3 4 next page
Mostrar Somente
Refinado por: assunto: Type 2 Diabetes remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Material Type:
Artigo 		Adicionar ao Meu Espaço

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Schnell, Oliver ; Barnard-Kelly, Katharine ; Battelino, Tadej ; Ceriello, Antonio ; Larsson, Helena Elding ; Fernández-Fernández, Beatriz ; Forst, Thomas ; Frias, Juan-Pablo ; Gavin, 3rd, James R ; Giorgino, Francesco ; Groop, Per-Henrik ; Heerspink, Hiddo J L ; Herzig, Stephan ; Hummel, Michael ; Huntley, George ; Ibrahim, Mahmoud ; Itzhak, Baruch ; Jacob, Stephan ; Ji, Linong ; Kosiborod, Mikhail ; Lalic, Nebosja ; Macieira, Sofia ; Malik, Rayaz A ; Mankovsky, Boris ; Marx, Nikolaus ; Mathieu, Chantal ; Müller, Timo D ; Ray, Kausik ; Rodbard, Helena W ; Rossing, Peter ; Rydén, Lars ; Schumm-Draeger, Petra-Maria ; Schwarz, Peter ; Škrha, Jan ; Snoek, Frank ; Tacke, Frank ; Taylor, Bruce ; Jeppesen, Britta Tendal ; Tesfaye, Solomon ; Topsever, Pinar ; Vilsbøll, Tina ; Yu, Xuefeng ; Standl, Eberhard

Cardiovascular diabetology, 2024-03, Vol.23 (1), p.104-104 [Periódico revisado por pares]

England: BioMed Central

Texto completo disponível

Citações Citado por
2
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes

Saxena, Aditi R. ; Frias, Juan P. ; Gorman, Donal N. ; Lopez, Rene N. ; Andrawis, Nabil ; Tsamandouras, Nikolaos ; Birnbaum, Morris J.

Diabetes, obesity & metabolism, 2023-10, Vol.25 (10), p.2805-2814

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
3
A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial
A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

A microbiome‐targeting fibre‐enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double‐blind, randomized, placebo‐controlled trial

Frias, Juan P. ; Lee, Martin L. ; Carter, Matthew M. ; Ebel, Emily R. ; Lai, Ren‐Hau ; Rikse, Lars ; Washington, Marc E. ; Sonnenburg, Justin L. ; Damman, Christopher J.

Diabetes, obesity & metabolism, 2023-05, Vol.25 (5), p.1203-1212

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
4
iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study
Material Type:
Artigo 		Adicionar ao Meu Espaço

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

McCrimmon, Rory J. ; Cheng, Alice Y.Y. ; Galstyan, Gagik ; Djaballah, Khier ; Li, Xuan ; Coudert, Mathieu ; Frias, Juan P.

Diabetes, obesity & metabolism, 2023-01, Vol.25 (1), p.68-77

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
5
Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles
Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles

Bergenstal, Richard M. ; Johnson, Mary L. ; Aroda, Vanita R. ; Brazg, Ronald L. ; Dreon, Darlene M. ; Frias, Juan P. ; Kruger, Davida F. ; Molitch, Mark E. ; Mullen, Deborah M. ; Peyrot, Mark ; Richter, Sara ; Rosenstock, Julio ; Serusclat, Pierre ; Vance, Carl ; Weinstock, Ruth S. ; Levy, Brian L.

Journal of diabetes science and technology, 2022-09, Vol.16 (5), p.1167-1173 [Periódico revisado por pares]

Los Angeles, CA: SAGE Publications

Texto completo disponível

Citações Citado por
6
Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy
Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long‐term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104‐week extension to a 52‐week randomized, phase 3 study and liver fat MRI substudy

Frías, Juan P. ; Maaske, Jill ; Suchower, Lisa ; Johansson, Lars ; Hockings, Paul D. ; Iqbal, Nayyar ; Wilding, John P. H.

Diabetes, obesity & metabolism, 2022-01, Vol.24 (1), p.61-71

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
7
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
Material Type:
Artigo 		Adicionar ao Meu Espaço

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11

Frias, Juan P. ; Bonora, Enzo ; Cox, David A. ; Bethel, M. Angelyn ; Kwan, Anita Y.M. ; Raha, Sohini ; Malik, Raleigh E.

Diabetes, obesity & metabolism, 2021-12, Vol.23 (12), p.2819-2824

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
8
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
Material Type:
Artigo 		Adicionar ao Meu Espaço

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11

Van, Joanna ; Frias, Juan P. ; Bonora, Enzo ; Raha, Sohini ; Meyer, Jarrett ; Jung, Heike ; Cox, David ; Konig, Manige ; Peleshok, Jennifer ; Bethel, M. Angelyn

Diabetes therapy, 2021-10, Vol.12 (10), p.2783-2794

Cheshire: Springer Healthcare

Texto completo disponível

Citações Citado por
9
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial

Frias, Juan P. ; Bonora, Enzo ; Nevárez Ruiz, Luis ; Hsia, Stanley H. ; Jung, Heike ; Raha, Sohini ; Cox, David A. ; Bethel, M. Angelyn ; Konig, Manige

Diabetes, obesity & metabolism, 2021-10, Vol.23 (10), p.2279-2288

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
10
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11

Bonora, Enzo ; Frias, Juan P. ; Tinahones, Francisco J. ; Van, Joanna ; Malik, Raleigh E. ; Yu, Zhuoxin ; Mody, Reema ; Bethel, Angelyn ; Kwan, Anita Y. M. ; Cox, David A.

Diabetes, obesity & metabolism, 2021-10, Vol.23 (10), p.2242-2250

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (17)

Data de Publicação 

De até
Refinar
  1. Antes de2008  (3)
  2. 2008Até2010  (3)
  3. 2011Até2016  (3)
  4. 2017Até2019  (11)
  5. Após 2019  (16)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.